A-90 Day Gavage Safety Assessment of Boswellia serrata in Rats


Affiliations

  • Jamia Hamdard University
  • Arjuna Natural Extracts Ltd, Kerala, India

Abstract

The present study deals with the evaluation and assessment of the safety/toxic potential of Boswellia serrata, a well known Ayurvedic herb used to treat disorders of digestive system, respiratory ailments and bone related diseases. A repeated dose oral (90 days) toxicity study of Boswellia serrata was carried out. For this, 10 rats of each sex were treated with the Boswellia serrata at three different doses i.e. 100, 500 and 1000 mg/kg B. wt. /day. As a control, 10 rats of each sex were treated with corn oil only which was the vehicle. Two groups consisting of five male and five female rats were kept as control recovery and high dose recovery group which were treated with the vehicle (corn oil) and the Boswellia serrata at the dose of 1000 mg/kg B. wt. Animals of control recovery and high dose recovery groups were further observed for 28 days without any treatment. From this study, it was found that the rats treated with high dose of the Boswellia serrata gained their body weight with much less rate than that of the control group. However, during the recovery period, the loss in body weight gain as observed during the study period exhibits a reversible effect on the metabolic activity and recovered. The results also indicate that Boswellia serrata is relatively safe in rat up to the dose of 500 mg/kg B.wt. as no adverse impact on health factors was observed. Thus, the No observed adverse effect level is 500 mg/kg B. wt.

Keywords

Boswellia serrata, NOAEL, safety, sub-chronic, toxicity, wistar rat

Full Text:

References

Alternative Medicine Review volume 13, number 2 2008.

Singh GB, Atal CK. Pharmacology of an extract of Salai guggal ex-Boswellia serrata, A new non steroidal anti-inflammatory agent. Agents Actions 1986; 18:407-12.

Sharma ML, Bani S, Singh GB. Anti-arthritic activity of boswellicacids in bovine serum albumin (BSA)-induced arthritis.Int J Immunopharmacol 1989; 11:647-52.

Gupta I, Parihar A, Malhotra P, Gupta S, Ludtke A, Safayhi H, et al.Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001; 67:391-5.

Gupta I, Gupta V, Parihar A, Gupta S, Ludtke R, Safayhi H, et al.Effects of Boswellia serrata gum resin in patients with bronchial asthma: Results of a double-blind, placebo controlled, 6-week clinical study. Eur J Med Res 1998; 3:511-4.

Chopra RN, Nayar SL, Chopra IC. Glossary of Indian medicinal plants. New Delhi: Council of Industrial and Scientific Research; 1956. p. 39.

Pandey RS, Singh BK, Yamini B. Tripathi, Extract Of Gum Resins Of Boswellia serrata L. Inhibits Lipopolysaccheriode Induced Nitric Oxide Production In Rat Macrophages Along With Hypolipidemic Property. Indian J Exp Biol 2005; 43:509-6.

Shao Y, Ho CT, Chin CK, Badmaev V, Ma W, Huang MT. Inhibitory activity of Boswellic acids from Bosweliia serrata against human leukemia HL-60 cells in culture. Planta Med 1998; 64:328-31.

Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon HP. Boswellic acids: Novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 1992; 261:1143-6.

Ammon HP, Safayhi H, Mack T, Sabieraj J. Mechanism of antiinflammatory actions of curcumin and boswellic acids.J Ethnopharmacol 1993; 38:113-9.

Wildfeuer A, Neu IS, Safayhi H, Metzger G, Wehrmann M, Vogel U, et al. Effects of boswellic acids extracted from a herbal medicine on the biosynthesis of leukotrienes and the course of experimental autoimmune encephalomyelitis.Arzneimittelforschung 1998; 48:668-74.

Safayhi H, Boden SE, Schweizer S, Ammon HP. Concentrationdependent potentiating and inhibitory effects of Boswelliaextracts on 5-lipoxygenase product formation in stimulated PMNL. Planta Med 2000; 66:110-3.

OECD Guideline (1998). No. 408 for Testing of Chemicals.“Repeated Dose 90 day Oral Toxicity Study in Rodents” adopted on September 21, 1998.

WHO. General Guidelines for Methodologies on Research and evaluation of Traditional Medicine. Geneva: WHO; 2000.

Safayhi H, Sailer ER, Amnon HPT. 5-lipoxygenase inhibition by acetyl-11-keto-b-boswellic acid. Phytomedicine 1996; 3:71-2.


Refbacks

  • There are currently no refbacks.